Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials
- Citation:
- Cancer Res vol 79 (4_suppl) abstr PD3-02
- Meeting Instance:
- SABCS 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3041
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U24CA196171; NRG- U10CA180868 (NCTN), UG1CA189867 (NCORP), U10CA180822 (NRG Oncology SDMC [Biostats]), U24CA196067 (BSB) (Lab)
- Corr. Author:
- Authors:
- Saranya Chumsri Zhou Li Daniel J. Serie Afshin Mashadi-Hossein Gerardo Colon-Otero Nan Song Katherine L. Pogue-Geile Patrick Gavin Soon Paik Alvaro Moreno-Aspitia Edith A. Perez E. Aubrey Thompson
- Networks:
- LAPS-MN026, PR028
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N9831, NSABP B-31
- Phases:
- 3
- Keywords: